In patients with a rare and aggressive form of leukodystrophy, a class of targeted therapy drugs could help improve their neurological function, revealed new findings published today in the New England Journal of Medicine.
Aicardi-Goutières syndrome (AGS) is a rare genetic disorder and type of leukodystrophy that affects the brain and immune system. In patients with AGS, the body's immune system turns on itself in a destructive way, targeting the brain's white matter, causing most children with the disorder to experience mild to severe intellectual or physical impairments. Most children with AGS are unable to walk or talk and have multisystemic complications, including skin inflammation.
Achondroplasia
Achondroplasia is a rare genetic disorder of bone growth that causes short-limbed dwarfism. It occurs due to mutations in a single gene called the FGFR3.
Advertisement
‘A JAK inhibitor helped patients with Aicardi-Goutières Syndrome, a rare genetic disorder meet important developmental milestones. ’
Tweet it Now
Prior studies have linked the activation of interferons - signaling proteins that respond to various immune disruptions - to exacerbated symptoms in AGS. Researchers at CHOP wanted to explore whether a class of small molecule inhibitor drugs called janus kinase (JAK) inhibitors could be used to block interferon activation in a way that helped these patients.
"Because treatment options for AGS are limited and the symptoms that these patients experience are so severe, there is a need to explore a wide variety of options," said senior author Adeline Vanderver, MD, an attending physician in the Division of Neurology, Program Director of the Leukodystrophy Center, and Jacob A. Kamens Endowed Chair in Neurologic Disorders and Translational Neurotherapeutics at CHOP.
![New Insights into Cleidocranial Dysplasia (CCD), a Rare Disorder]( "New Insights into Cleidocranial Dysplasia (CCD), a Rare Disorder")
Cleidocranial dysplasia (CCD) is a rare disorder of which the most prominent features are missing or abnormal growth of the teeth and collarbones.
The study was conducted at CHOP with 35 international patients with genetically confirmed AGS. These patients received baricitinib, an oral JAK1 and JAK2 inhibitor, with doses based on each patient's renal function, age and symptoms. Patients had their developmental histories evaluated from the onset of the disease to the end of the study, which ranged from 7.4 months to 41.5 months. The study team analyzed a variety of developmental milestones, including head control, sitting, rolling, smiling, babbling, and the use of single words and word combinations.
Before the patients in this study received treatment, 26 of the 35 had stable or declining neurologic function, and 9 of the 35 patients gained one or two of these developmental skills after disease onset. However, during the study, 20 patients met new milestones, and 12 patients gained between two to seven new skills. The improvements were typically observed within three months into the study and persisted. Children who received higher doses of the therapy appeared to achieve more of these milestones.
Some of the AGS patients who received baricitinib were at risk for developing thrombocytosis, leukopenia, and infection and therefore should be monitored closely while taking the drug.
"Measuring neurologic improvements in these patients is a complex process, but the results of this study are encouraging, especially because we observed improvements even in patients with severe and long-standing disease," Vanderver said.
Source: Eurekalert
New Insights into Cleidocranial Dysplasia (CCD), a Rare Disorder
Cleidocranial dysplasia (CCD) is a rare disorder of which the most prominent features are missing or abnormal growth of the teeth and collarbones.
Advertisement
The study was conducted at CHOP with 35 international patients with genetically confirmed AGS. These patients received baricitinib, an oral JAK1 and JAK2 inhibitor, with doses based on each patient's renal function, age and symptoms. Patients had their developmental histories evaluated from the onset of the disease to the end of the study, which ranged from 7.4 months to 41.5 months. The study team analyzed a variety of developmental milestones, including head control, sitting, rolling, smiling, babbling, and the use of single words and word combinations.
Before the patients in this study received treatment, 26 of the 35 had stable or declining neurologic function, and 9 of the 35 patients gained one or two of these developmental skills after disease onset. However, during the study, 20 patients met new milestones, and 12 patients gained between two to seven new skills. The improvements were typically observed within three months into the study and persisted. Children who received higher doses of the therapy appeared to achieve more of these milestones.
Some of the AGS patients who received baricitinib were at risk for developing thrombocytosis, leukopenia, and infection and therefore should be monitored closely while taking the drug.
"Measuring neurologic improvements in these patients is a complex process, but the results of this study are encouraging, especially because we observed improvements even in patients with severe and long-standing disease," Vanderver said.
Source: Eurekalert
Internet may be a Valuable Tool for People with Undiagnosed Rare Disorders
Internet can serve as a helpful pathway to diagnosis and care for people who suspect they have a rare disorder that has not been identified by their physicians, reveals a new study
Advertisement
 Antibodies in Patients With Rare Disorder may Prevent Type 1 Diabetes and PsoriasisThe antibodies were derived from people with a rare autoimmune disorder, called autoimmune polyendocrine syndrome type 1 (APECED). | Advertisement
|
Advertisement
Recommended Readings
Latest Genetics & Stem Cells News
Among MS patients, the stem cells showed a neuroprotective role, guarding nerve cells from further decline.
New possibilities for research on digestive diseases have been set by complete decoding of the Y chromosome.
UK has given the green light to the world's inaugural gene therapy for sickle-cell disease and thalassemia.
1 in 25 people had a genotype linked to short lifetime, which includes BRCA2 and LDLR genes, that reduced lifespan by seven years, and six years respectively.
The study findings help redefine osteoarthritis as a reversible loss of key cartilage stem cells, not just 'wear and tear'."